March 2026 Quarterly Activity Report & Appendix 4C
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The report highlights the approval of Nasodine Nasal Spray in Indonesia and the launch of Nasodine Throat Spray in Singapore and Fiji. Additionally, the company announced key appointments aimed at enhancing its growth in the North American market and successfully raised new funds through a private placement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Firebrick Secures $1.5 million via Placement
- Trading Halt
- Registration Agreement and Approval of Nasodine in Indonesia
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- December 2025 Quarterly Activity Report & Appendix 4C
Later from Firebrick Pharma
- Investor Update
- Appendix 4E and Annual Report 30 June 2026
- Firebrick receives $293,000 R&D Tax Incentive
- Firebrick announces USA Retail Launch Plan
- Firebrick Secures $732k in Strategic Investments
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma